Regulation - Revlimid

Filter

Current filters:

Revlimid

Popular Filters

NICE consulting again on Celgene's Revlimid for multiple myeloma

NICE consulting again on Celgene's Revlimid for multiple myeloma

31-07-2014

The UK clinical guidance body, the National Institute for Health and Care Excellence (NICE), is again…

Celgene Corp.ImmunosuppressantslenalidomideOncologyPharmaceuticalRegulationRevlimidUK

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

Negative draft NICE guidance on Celgene’s Revlimid for myelodysplastic syndromes

24-10-2013

The UK drug watchdog the National Institute for Health and Care Excellence (NICE) today issued final…

BiotechnologyCelgeneEuropeOncologyRegulationRevlimid

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

US FDA backs new indication for Celgene's Revlimid

06-06-2013

The US Food and Drug Administration has approved US biotech firm Celgene's (Nasdaq: CELG) supplemental…

BiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Celgene's Revlimid approved in China for MM; gets PDUFA date in USA for mantle cell lymphoma

12-02-2013

Celgene Corp's (Nasdaq: CELG) European subsidiary revealed that Revlimid (lenalidomide) has been granted…

Asia-PacificBiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Celgene slumps as it pulls new EU indication filing for Revlimid

22-06-2012

Celgene International, the European subsidiary of USA-based Celgene Corp (Nasdaq: CELG), has provided…

BiotechnologyCelgeneEuropeFinancialOncologyPharmaceuticalpomalidomideRegulationRevlimid

US FDA warns on safety of Celgene's Revlimid; new Ph III trial results

11-05-2012

The US Food and Drug Administration this week issued a notification of an increased risk of second primary…

BiotechnologyCelgeneOncologyRegulationResearchRevlimid

Company Spotlight

ImmunoGen

ImmunoGen

Back to top